Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1991 1
1994 3
1995 2
1996 1
1998 2
1999 1
2001 1
2003 2
2004 1
2005 1
2008 1
2009 4
2010 4
2011 6
2012 2
2013 7
2014 4
2015 9
2016 4
2017 7
2018 6
2019 8
2020 6
2021 7
2022 15
2023 13
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Results by year

Filters applied: . Clear all
Page 1
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME, Nair P, Terrier B, Walz B, Bourdin A, Jayne DRW, Jackson DJ, Roufosse F, Börjesson Sjö L, Fan Y, Jison M, McCrae C, Necander S, Shavit A, Walton C, Merkel PA; MANDARA Study Group. Wechsler ME, et al. N Engl J Med. 2024 Mar 7;390(10):911-921. doi: 10.1056/NEJMoa2311155. Epub 2024 Feb 23. N Engl J Med. 2024. PMID: 38393328 Clinical Trial.
Treatments of refractory eosinophilic lung diseases with biologics.
Asano K, Suzuki Y, Tanaka J, Kobayashi K, Kamide Y. Asano K, et al. Among authors: kamide y. Allergol Int. 2023 Jan;72(1):31-40. doi: 10.1016/j.alit.2022.10.004. Epub 2022 Nov 1. Allergol Int. 2023. PMID: 36333218 Free article. Review.
Increased Circulating Cell-Free DNA in Eosinophilic Granulomatosis With Polyangiitis: Implications for Eosinophil Extracellular Traps and Immunothrombosis.
Hashimoto T, Ueki S, Kamide Y, Miyabe Y, Fukuchi M, Yokoyama Y, Furukawa T, Azuma N, Oka N, Takeuchi H, Kanno K, Ishida-Yamamoto A, Taniguchi M, Hashiramoto A, Matsui K. Hashimoto T, et al. Among authors: kamide y. Front Immunol. 2022 Jan 12;12:801897. doi: 10.3389/fimmu.2021.801897. eCollection 2021. Front Immunol. 2022. PMID: 35095884 Free PMC article.
Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD.
Taniguchi M, Mitsui C, Hayashi H, Ono E, Kajiwara K, Mita H, Watai K, Kamide Y, Fukutomi Y, Sekiya K, Higashi N. Taniguchi M, et al. Among authors: kamide y. Allergol Int. 2019 Jul;68(3):289-295. doi: 10.1016/j.alit.2019.05.001. Epub 2019 Jun 21. Allergol Int. 2019. PMID: 31235242 Free article. Review.
Omalizumab ameliorates extrarespiratory symptoms in patients with aspirin-exacerbated respiratory disease.
Hayashi H, Fukutomi Y, Mitsui C, Kajiwara K, Watai K, Tomita Y, Kamide Y, Tsuburai T, Sekiya K, Ishii M, Hasegawa Y, Taniguchi M. Hayashi H, et al. Among authors: kamide y. J Allergy Clin Immunol. 2023 Jun;151(6):1667-1672.e2. doi: 10.1016/j.jaci.2023.03.014. Epub 2023 Mar 24. J Allergy Clin Immunol. 2023. PMID: 36967017 Free article. Clinical Trial.
[EOSINOPHILIC GRANULOMATOSIS WITH POLYANGITIS (EGPA)].
Taniguchi M, Sekiya K, Kamide Y, Fukutomi Y, Watai K, Hamada Y, Nakamura Y, Ryu K, Fujita N, Yano K, Iwata M, Nagayama K, Mori A. Taniguchi M, et al. Among authors: kamide y. Arerugi. 2020;69(5):293-303. doi: 10.15036/arerugi.69.293. Arerugi. 2020. PMID: 32684542 Japanese. No abstract available.
Deep metric learning for otitis media classification.
Sundgaard JV, Harte J, Bray P, Laugesen S, Kamide Y, Tanaka C, Paulsen RR, Christensen AN. Sundgaard JV, et al. Among authors: kamide y. Med Image Anal. 2021 Jul;71:102034. doi: 10.1016/j.media.2021.102034. Epub 2021 Mar 14. Med Image Anal. 2021. PMID: 33848961 Free article.
108 results